Search

everythinglearnresearchcommunity

for

Search:↓

Oral Minoxidil can cause puffy eyes and fluid retention. Adding an ACE inhibitor or ARB, like Telmisartan, may help mitigate these side effects.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

The user experienced chest soreness and mild gynecomastia after taking 1mg finasteride three times a week, which resolved after stopping the medication. They are considering trying a lower dose or topical finasteride to avoid side effects.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

A 23-year-old experiencing severe diffuse thinning after scalp inflammation is considering finasteride as a last resort after stopping minoxidil and using anti-inflammatory medication. Users suggest that inflammation causes temporary shedding and recommend consulting a dermatologist, with some advocating for finasteride as a reliable treatment option.

The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.

The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.

The conversation discusses using cetirizine (Zyrtec) topically to relieve scalp itch associated with hair loss and suggests it may also benefit androgenetic alopecia (AGA). One person found relief from scalp itch after three months on finasteride, noting the itch was linked to areas where hair was lost.

User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user is using topical dutasteride, finasteride, minoxidil, and tretinoin but seeing no results or side effects. They also microneedle every two weeks but experience little bleeding, questioning if a thick scalp is preventing treatment effectiveness.

A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.

The user has been taking 1mg finasteride daily for a year with no improvement in hair loss and reports low cortisol levels, sleep issues, and anxiety changes. The conversation includes discussions on the potential effects of finasteride on cortisol and neurosteroids, with suggestions to consult a doctor and consider other factors.

A 43-year-old from Thailand shares progress after 1 month using topical finasteride, minoxidil, tretinoin cream, and weekly microneedling for diffused thinning. Users compliment his appearance and suggest he doesn't need treatment.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.

This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

An 18-year-old experienced chest pain, headaches, and vomiting after taking oral minoxidil for hair loss. They reduced the dosage, felt better, but experienced sharp chest pain again after increasing it, and are advised to stop the medication and see a doctor.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

A 24-year-old with mild temple recession is using 5% minoxidil without noticeable effects and has started topical finasteride but is anxious about potential side effects. They are considering a specialist visit for peace of mind despite the cost.

The user experienced severe side effects from finasteride and is considering a combination therapy including Minoxidil, Tretinoin, microneedling, caffeine, and other ingredients. They are also thinking about adding red light therapy and microneedling once per week.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.